Does broad Borrelia IgG reactivity indicate exposure to multiple Borrelia antigens?

Broad Borrelia IgG reactivity can be biologically meaningful, but it is primarily evidence of an immune response—not a direct measure of current infection or organism viability.

Clinical interpretation of broad IgG reactivity

• Concurrent reactivity to C6, VlsE1, whole-cell material, BmpA, OspB, p28, and p41 is plausibly consistent with antibodies binding multiple Borrelia-derived antigens. Multiprotein reactivity generally has greater specificity than a single reactive antigen.
• This exact pattern is not, however, independently diagnostic of Lyme disease or active Borrelia infection. p41 is relatively nonspecific because flagellin epitopes are conserved across organisms; VlsE and BmpA may cross-react; and C6/VlsE reactivity is not species-specific and may occur with B. miyamotoi.
• Interpretation is most reliable when testing uses a validated FDA-cleared standard or modified two-tier algorithm and is integrated with compatible symptoms, exposure likelihood, and prior Lyme history.

Viability and persistence

• Serology measures host antibodies rather than live organisms. IgG—and even IgM—may remain detectable for years to decades after infection has cleared.
• In a cohort assessed 10–20 years after Lyme disease without active signs, IgG remained positive in 25% after prior early Lyme disease and 62% after prior Lyme arthritis; IgM persisted in 10% and 15%, respectively.
• PCR positivity also does not prove viability, since nucleic acid can persist after treatment. Confirmed growth in culture is evidence of viable organisms, but culture has low, specimen-dependent sensitivity and is not a practical routine test.

Bottom line

• Broad IgG reactivity plausibly reflects recognition of several Borrelia antigens, but cross-reactivity and durable antibody persistence limit its specificity. Antibodies alone cannot establish that viable Borrelia remain present or that ongoing symptoms represent persistent infection.